Refinement of strategies for the development of a human cytomegalovirus dense body vaccine
- First Online:
- Cite this article as:
- Mersseman, V., Böhm, V., Holtappels, R. et al. Med Microbiol Immunol (2008) 197: 97. doi:10.1007/s00430-008-0085-2
- 358 Views
Development of a vaccine against human cytomegalovirus (HCMV) infection has been identified as a high priority goal in biomedical research, yet no vaccine has been licensed until now. Recombinant subviral dense bodies (recDB) are a promising basis for the establishment of such a vaccine. In this article, strategies for the generation of recDB, based on recombination-mediated genetic engineering of the 230 kb HCMV DNA genome in E. coli are outlined. Analysis of viral mutants that were constructed in this process provided the proof-of-principle that heterologous antigens can be packaged into recDB and that these particles prime CD8 T cell responses against the recombinant antigen upon their application to HLA-A2 transgenic mice.
Infections with human cytomegalovirus (HCMV) continue to be important complications of allogeneic hematopoietic stem cell transplantation (HSCT) . Prenatal HCMV infection, in addition, is the leading cause of mental retardation and sensorineural hearing loss in infants in the Western world [2, 3], and it may also contribute to morbidity and mortality in newborns in developing countries . Numerous studies have found a strong correlation of immature or impaired immune defence functions with morbidity and mortality second to HCMV infection or reactivation . Cytolytic CD8 T lymphocytes (CTL) have been denominated as key effectors that control viral infection and limit viral reactivation, both in animal models and in clinical studies [5–7]. Consequently, work performed to develop immunotherapeutic or prophylactic intervention strategies against HCMV disease has focused on the enhancement of CD8 and CD4 T cell responses [8–10]. Although the role of T lymphocytes in the prevention of prenatal HCMV infection and disease remains controversial, there is no doubt that improved reconstitution of CD8 and CD4 T cells is a primary goal of HCMV specific immunotherapy in allogeneic HSCT [1, 11].
Success of therapeutic tumor intervention applying allogeneic HSCT is frequently compromised by HCMV reactivation . Depletion of donor-derived lymphocytes to reduce graft-versus-host disease is one risk factor in this context, as antiviral T cells may be concomitantly depleted . Selective removal of only the alloreactive T cells may be a way to retain antiviral CD8 responses [13, 14]. Transfer of antiviral T cell lines, generated by in vitro stimulation prior to transfusion, has been shown to be another option to reconstitute HCMV immune responses [7–9]. However, logistic limitations and the possible risk of transfer of alloreactive cells together with HCMV specific cells have prevented introduction of such strategies as a clinical routine. T cell receptor (TCR-) based ex vivo sorting of antiviral CD8 T cells and subsequent adoptive transfer of such cells has been shown to be effective to reduce the incidence of cytomegalovirus induced disease in a mouse model [15, 16], and it has also been applied in first clinical studies . However, a number of questions regarding the adoptive transfer of HCMV-specific T lymphocytes remain unanswered. Most importantly, the effectiveness of such a procedure to confer lasting protection against HCMV disease after HSCT remains undetermined. Furthermore, it may not be possible to generate HCMV specific T-lymphocytes from HCMV-seronegative donors. One way to improve the potency of the HCMV specific adoptive T cell transfer for immunoprophylaxis is the use of a vaccine for in vivo stimulation of transferred T cells.
Several vaccine candidates have been introduced, none of which has entered clinical routine, yet [17–20]. We have focused on the development of a vaccine based on subviral dense bodies (DB) [21, 22]. DB enter cells in a way comparable to virions and thereby deliver their proteinaceous content into the cytoplasm. As exemplified for the major component of DB, the pp65 (ppUL83), peptides derived from this tegument protein are efficiently introduced into the MHC class I presentation pathway without requiring de novo protein synthesis . Although pp65 by itself is a prominent target of the CD4 and CD8 T cell responses following natural infection [23–25], other proteins like the non-structural, regulatory IE1-protein (ppUL123) are also targeted by the immune system [26, 27]. Consequently, inclusion of such antigens in a vaccine formulation may be important to induce a broad immune response [15, 26–30]. We have started a project to broaden the antigenic content of DB. Viral mutants that expressed pp65 in fusion with a heterologous polypeptide were generated. Cells infected with these viruses released recombinant DB (recDB) containing the fusion protein, thus proving the feasibility of the approach . This strategy, however, had to be refined with respect to the numbers of recDB released from infected cells. In addition, the methodology of conventional recombination in eukaryotic cells, used for these experiments, may be critical in the development of a vaccine for human application.
The aim of the work described in this article was to define a location within pp65 that allowed fusion with a heterologous polypeptide while retaining efficient release of recDB from HCMV infected cells. For this, we used two different variations of recombination-mediated genetic engineering (recombineering) of bacterial artificial chromosome (BAC) clones of the virus to modify the 230 kb HCMV genome in E. coli [32–35]. For the sake of this experimental approach, we decided to fuse fragments of the IE1 protein of HCMV, containing HLA-A2 presented peptide determinants, to pp65. For analysis, an antibody tag for an epitope from the c-myc gene was included in some of the recombinants. The respective viral mutants were reconstituted in human foreskin fibroblasts (HFF) and were subsequently analysed for synthesis and release of recombinant particles by infected HFF.
Materials and methods
Generation of BAC clones by positive selection using kanamycin resistance (KanR)
The generation of HCMV BACs, using positive selection, was performed according to Lee et al. .
Cloning of BAC-SR1
Sequences of the oligonucleotides used for PCR-amplification
Used to construct
GAGA GGA TCC TGA CAC CAG AGA ATC AGA GGA GC
pK65-1 for pBAC-EP1 cloning
pK65-1 for pBAC-EP1 cloning
pK65-2 for pBAC-EP2 cloning
pK65-2 for pBAC-EP2 cloning
pK65-0 for pBAC-EP0 cloning
pK65-0 for pBAC-EP0 cloning
Cloning of BAC-VR1
For the construction of the C-terminal pp65 fusion protein, the primer pair SR9/SR10 (Table 1) was used to amplify the FRT-KanR-FRT cassette from the plasmid template pCP-IE1. The NsiI cleaved PCR-fragment was inserted into NsiI cleaved pBamHIR, a pBluescript based plasmid containing the BamHI R fragment  of HCMV with the complete pp65 gene. The resulting plasmid pBamHIR-Kan, with the FRT-KanR-FRT cassette downstream of pp65 was digested with NheI and ligated with the NheI digested PCR-fragment of the template plasmid pCP-IE1 and primers SR11/SR12. This step adds the IE1(288–402)-fragment to the C-terminus of pp65. The construct was termed pBamHIR-IE1-Kan. This plasmid was used as template with primers SR13/SR14 to amplify the PCR-fragment for the homologous recombination into pHB5.
Cloning of BAC-EP0, BAC-EP1, BAC-EP2
To generate pp65-fusion proteins labelled with a myc tag, a PCR product was generated using pBamHIR-Kan as template and the SR16/SR17 primer pair (Table 1) for amplification. The resulting fragment was inserted into a TA cloning vector and the plasmid was termed pK65. Plasmid pK65 contained the 3′ end of UL83 with an adjacent FRT-KanR-FRT cassette. In order to construct the pK65-0 plasmid, the complementary oligonucleotides SR26 and SR27, which carried the nucleic acid sequence of a c-myc tag and a stop codon flanked by NheI restriction sites, were annealed. This annealing product was then digested with NheI and sub-cloned into a NheI digested pK65 plasmid.
The sequences coding for the IE1 peptides IE1(288–309) and IE1(309–328) were amplified by PCR using the pCP-IE1 plasmid with the respective forward primers (SR24, SR22) containing a NheI restriction site, and with the respective reverse primers (SR25, SR23), containing sequences of a c-myc tag, a stop codon and a NheI restriction site. The pK65-1 plasmid, carrying the coding sequence for the IE1(288–309) peptide, and the pK65-2 plasmid, containing the coding sequence for the IE1(309–328) peptide, were obtained by sub-cloning the different NheI digested PCR products into the NheI digested pK65 plasmid. To fuse the different IE1 fragments at the C-terminus of pp65 into the HCMV BAC, PCR fragments were generated using primers SR16/SR17 and plasmid pK65-1 resulting in BAC-EP1, or plasmid pK65-2 for BAC-EP2, or plasmid pK65-0 for BAC-EP0. The correct nucleotide sequences of all plasmids and BACs were verified by sequencing the modified regions. All used primers are listed in Table 1.
Construction of recombinant viruses expressing N- and C-terminal fusion proteins of pp65
Expression and packaging of the N- and C-terminal pp65-IE1 fusion proteins in infected cells
To analyse the subcellular localisation of the fusion proteins, indirect immunofluorescence analyses were performed (Fig. 2b). Cells infected with RV-HB5 showed the well-established nuclear localisation of pp65 at 2 days p.i. and the cytoplasmic shift at 4 d.p.i.. In cells infected with RV-VR1, pp65 was only vaguely detectable at 2 days p.i., and was localized in the cytoplasm at 4 days p.i.. In cells infected with the RV-EP0 and RV-EP1, the fusion protein was translocated from the nucleus to the cytoplasm during later stages of infection. This was comparable to the parental strain. In contrast, in cells infected with RV-EP2, the fusion protein remained mainly in the nucleus. To test whether the fusion proteins of the different viral mutants were incorporated into extracellular progeny viral particles, the different particle fractions were separated by glycerol–tartrate gradient centrifugation of culture supernatants from infected cells  (data not shown). The gradient obtained from RV-HB5 infected cells showed the typical banding pattern of HCMV viral particles, consisting of NIEPs, virions and DB. In the gradients from RV-VR1, RV-EP1 and RV-EP2 infected cells, the NIEPs and virion bands, but no DB were detectable. Only in the RV-EP0 gradient, a faint smear of DB became apparent. Because bands corresponding to DB were absent in the gradients from RV-VR1, RV-EP1 and RV-EP2 and because the material from the virion fractions was not sufficient for further analysis, only bands from the NIEPs fractions were collected and subjected to immunoblot analyses (Fig. 2c). The pp65-c-myc fusion protein from RV-EP0 appeared to be packaged with similar abundance compared to the wild type pp65 tegument protein. In contrast to that, lower amounts of the fusion proteins from RV-VR1, RV-EP1 and RV-EP2 were detected in the respective NIEPs fractions. These results showed that infection with these three recombinant viruses leads to decreased packaging of the respective pp65-IE1 fusion proteins into viral particles compared to infection with wild type RV-HB5. Taken together, fusion of heterologous partners to the very C-terminus may allow packaging of the fusion protein into NIEPs and virions to various extents, but it may be inappropriate for the generation of recDB.
Ultrastructural analysis of infected cells
Internal seamless fusion of heterologous peptide sequences to the viral pp65 by galK mediated recombineering
Immunologic potential of RV-VM3-dense bodies
In a recent paper, we could demonstrate by immunofluorescence analysis that the fusion protein of RV-VM3 behaves like wt pp65 with respect to its subcellular localization in infected HFF. Furthermore, RV-VM3-infected cells release both virions and DB that contain the fusion protein. The IE1TMY peptide is efficiently presented on the surface of cells exposed to the recombinant particles . However, one critical question remained open, namely whether an immune response against the recombinant antigen could be mounted after immunization with DB from RV-VM3 (DB-VM3).
In this communication, we have described experiments aiming at the modification of the protein composition of HCMV DB by fusing portions of a heterologous protein to pp65. Whilst the expression of N- and C-terminal pp65 fusion proteins in cells infected with the respective HCMV mutant viruses did not result in the release of significant numbers of recDB, the results obtained may well extend our understanding of the biology of pp65 and of HCMV particle morphogenesis.
Fusion of a heterologous polypeptide following the first ATG codon downstream of the transcription initiation site of the pp65 gene, as defined by Rüger et al. , led to a complete abrogation of pp65 protein expression in RV-SR1 infected cells. The reason for the lack of expression is unclear at the current stage. Depto and Stenberg  reported that, in transient transfection analyses, the octamer sequence ATTTCGGG found at position −51 with respect to the proposed transcription start site of the pp65 gene was essential for promoter activation. They identified the same sequence at position +93 and an inverted version at +67. There was no analysis performed on the relevance of these downstream sequences with respect to activation of the pp65 promoter. Both sequences were translocated, however, to a far downstream position by constructing the fusion gene in RV-SR1 (Fig. 1). Consequently, disrupting the downstream promoter structure could interfere with the expression of the N-terminal fusion protein. Alternatively, there may be additional transcription start sites downstream of position +93 that could be more important than the one described before .
The fusion proteins, with the exception of that of RV-EP2, were packaged into NIEPs. However, extracellular DB were, if at all, detectable only after infection with RV-EP0. From these analyses, it can be concluded that the formation of at least NIEPs containing pp65 fusion proteins was unaffected in RV-VR1-, RV-EP0-, and RV-EP1-infected cells. It may be assumed that also virion formation was unimpaired, although formal analyses still have to be performed to prove this. No DB formation, as compared with wt-infected cells, became apparent on the ultrastructural level. In accordance, cells infected with a pp65 negative virus released virions and NIEPs, but no DB . These results point towards a dichotomy in the ability of infected cells to package the pp65 fusion protein into DB and NIEPs. In contrast to the current understanding, this may indicate that formation and maybe also release of DB and NIEPs (or virions) follow separate pathways.
The fusion protein expressed by RV-EP2 was found in low amounts in extracellular NIEPs, although its expression level was indistinguishable from that of the fusion proteins of the other viruses. As a striking difference, the RV-EP2 fusion protein remained mainly in the nucleus at late times p.i.. Consequently, the defect of packaging of this protein in progeny particles seems to be related to an impaired nuclear export of this polypeptide. This cannot be explained by differences in size or position of the IE1-peptide fused to pp65, as both were identical for RV-EP1 and RV-EP2. Alternatively, the primary structure of the protein fused to the very C-terminus of pp65 may influence nuclear export and, as a consequence, packaging of the recombinant protein into viral particles. Further work has to be conducted to investigate this issue.
The work described in this article was experimental in nature to identify insertion sites within pp65, optimal for formation and release of recDB. However, it was not designed to procure a final vaccine candidate to be used in humans. For a final formulation, inclusion of undesired sequences like myc-tags or FRT-sites should be avoided. Using the positive selection procedure of BAC modification in combination with FLP-mediated excision will always leave behind operational traces, such as FRT-sites close to the insertion site. In contrast, employing galK for both positive and negative selection allows precise and seamless modification of the HCMV strain used for vaccine production and thus may be preferentially used to generate recDB.
The antigens, however, that should be included in such a recDB vaccine to provide a sufficient breadth of the immune response still need to be defined. For this, the diversity of human MHC class I haplotypes and of the antiviral CD8 T cell responses have to be considered. We could show here for the first time, yet, that recDB can prime a CD8 T cell response against an HLA-A2 presented model peptide, not normally contained in DB. Significant numbers of IE1-specific CD8 T cells could be detected after one or two rounds of in vitro restimulation, whereas the ex vivo frequency of these cells was very low (data not shown). Nevertheless, even very low numbers of ex vivo isolated IE1-specific CD8 T cells—namely 400 cells—are sufficient to effectively control CMV infection, as has been shown in the murine CMV infection model . In conclusion, the results of these initial immunization experiments are encouraging. However, further studies with the aim to refine the strategy of stimulating an HCMV specific T lymphocyte response, including serial immunizations and the use of adjuvant, need to be conducted.
Development of vaccines against human herpesviruses has proven to be a formidable endeavour. A wisdom that was accomplished in this process is that complex problems may not be successfully met by simple solutions. Translating this into biology means that complex infections, like that with herpesviruses, may not be successfully addressed with vaccines relying on single antigens. More elaborate formulations are needed to confer reliable protection. In the case of HCMV, DB may be a basis to achieve this noble goal of preventing disease by a vaccine. Recent implementation of recombineering methods to genetically engineer the HCMV genome in bacteria provides the opportunity to optimise the antigenic content of these particles. Different recDB can then be tested in vitro, e.g. for their capacity to stimulate human HCMV specific T cells. These approaches will help to finally establish a candidate vaccine. Such a vaccine may then be tested for its immunoprophylactic potential in combination with the adoptive transfer of TCR-sorted antiviral T lymphocytes. This strategy will preferentially be explored in murine challenge models and subsequently be investigated for its benefit on the level of clinical studies in HSCT patients.
The technical assistance of Manuela Starke and Elisabeth Sehn is gratefully acknowledged. We are indebted to Martin Messerle, Eva Borst, and Ulrich Koszinowski for HCMV BAC pHB5, to Neil Copeland for bacterial strains SW102 and EL250 and for pgalK, to François Lemonnier for the transgenic mouse strain HHD and RMA-S HHD cells, to Michael Mach for plasmid pCP-o-15-link2 and to William Britt for monoclonal antibodies. This work was supported by grants from the Deutsche Forschungsgemeinschaft, DFG Research Training Program 1043 “Antigen-Specific Immunotherapy” (V.M., S.R., and B.P.), SFB 490, individual projects E7 (B.P.) and E3 (V.B., P.D. and R.H.), and DFG-individual project Wo548-6 (U.W.).